British veterinary pharmaceutical company Genitrix has appointed four new account managers and reorganised its sales team to help it capitalise on strong demand for its ground-breaking therapies for companion animal and exotics.
British veterinary pharmaceutical company Genitrix has appointed four new Account Managers and reorganised its sales team. It says the move will help it capitalise on strong demand for its ground-breaking therapies for companion animal and exotics and enhance the level of service it provides to veterinary practices.
The four new recruits joined the firm in March and have boosted Genitrix’ existing sales team from eight to ten. They are:
- Meghan Styles – new Account Manager for East Anglia. She has a BSc in Applied Biology and worked in human pharmaceuticals before joining Genitrix. She is also a specialist in dog training and behaviour
- Sara Palmer – new Account Manager for Scotland and Ireland. Sara also has a BSc in Applied Biology and worked in agriculture and as a Territory Manager for Novartis before joining Genitrix.
- Roxie Murray – new Account Manager for the South East of England. Roxie is a newly qualified graduate with a BSc in Equine Veterinary Science.
- Issy Gray – new Account Manager for the South West of England. She has a BSc in Veterinary Anatomy from Bristol and worked in human pharmaceuticals before joining Genitrix.
Genitrix has also reorganised its sales force, giving its most experienced account managers, Owain Price and Angela Clark-Mayers, overall management responsibility for the West and East of the UK respectively. In their new regional manager positions, Mr Price and Miss Clark-Mayers will provide direction, guidance and advice to the account managers.
Managing director Howard Wilder said: “We have seen significant growth in our business already this year and, with the recent launch of Libromide, the first licensed treatment for canine epilepsy in the UK, we expect this growth to continue. We’ve invested in building up our sales team at this stage to ensure we’re well positioned to capitalise on the growing interest in our product range.”